+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tapentadol Market by Dosage Form, Product Type, Distribution Channel, Strength, End User, Application - Global Forecast to 2030- Product Image
Tapentadol Market by Dosage Form, Product Type, Distribution Channel, Strength, End User, Application - Global Forecast to 2030- Product Image
Sale

Tapentadol Market by Dosage Form, Product Type, Distribution Channel, Strength, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082595
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tapentadol Market grew from USD 4.10 billion in 2024 to USD 4.38 billion in 2025. It is expected to continue growing at a CAGR of 6.41%, reaching USD 5.96 billion by 2030.

Unveiling Tapentadol’s Strategic Market Foundations

Tapentadol represents a paradigm shift in analgesic therapy, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition to deliver targeted relief across acute and chronic pain indications. Its dual-mechanism profile mitigates the drawbacks of traditional opioids while maintaining robust efficacy, enabling clinicians to tailor dosing regimens with greater confidence. Since its introduction, tapentadol has garnered attention for its balanced safety and efficacy profile, prompting stakeholders to seek a deeper understanding of its evolving commercial landscape and long-term potential.

This executive summary synthesizes key intelligence on the tapentadol market, illuminating the forces driving its transformation. It explores the regulatory, economic, and competitive dynamics shaping product lifecycles, examines the ripple effects of recent tariff measures, and delivers granular segmentation insights. Additionally, regional patterns and competitive benchmarks are analyzed to equip decision-makers with a holistic perspective. Finally, strategic recommendations are presented to guide industry leaders in capitalizing on emerging opportunities and navigating potential challenges. Through this framework, the report delivers clarity and direction for shaping the future of tapentadol commercialization.

Pivotal Shifts Redefining Tapentadol Industry Dynamics

The tapentadol landscape is undergoing rapid evolution driven by regulatory milestones, shifting therapeutic paradigms, and advancements in patient-centric pain management. Recent approvals of extended-release formulations have strengthened its positioning in chronic pain management, while heightened scrutiny on opioid stewardship has underscored the importance of risk-mitigation strategies. Concurrent progress in abuse-deterrent technology has reinforced the value proposition of novel formulations and signaled a shift toward more responsible opioid prescribing practices.

Technological integration in patient engagement and remote monitoring has further transformed how therapy adherence and outcomes are measured, creating new pathways for differentiation. R&D investments are increasingly focused on abuse-deterrent innovations and novel delivery systems, reflecting a broader industry trend toward value-based care. Meanwhile, the proliferation of digital health platforms has enabled clinicians to individualize treatment plans and optimize dosing strategies based on real-world data. These combined forces have not only reshaped competitive dynamics but also accelerated the adoption of tapentadol as a versatile analgesic solution poised for sustained growth.

Assessing the Cumulative Impact of 2025 US Tariffs on Tapentadol Trade

The imposition of new United States tariffs in 2025 has introduced complex cost challenges for the tapentadol supply chain and pricing framework. Tariff escalations on key active pharmaceutical ingredients have elevated input costs, prompting manufacturers to reassess sourcing strategies and explore alternative supplier partnerships. These adjustments have yielded cascading effects on production timelines and inventory management, with companies prioritizing cost containment to preserve margin integrity.

In response to inflationary pressures, stakeholders have undertaken comprehensive cost-structure analyses to identify efficiencies across manufacturing, distribution, and procurement. Collaborative negotiations with contract manufacturers and distributors have intensified as firms seek to mitigate tariff impacts through volume discounts and localized sourcing. While short-term pricing pressures have emerged, the strategic realignment of supply chain networks and investment in domestic production capacities are expected to stabilize costs over the medium term. Overall, the 2025 tariff landscape has catalyzed a recalibration of operational strategies and underscored the critical importance of supply chain agility in maintaining competitive advantage.

Deep-Dive into Tapentadol Market Segmentation Insights

The tapentadol market encompasses a diverse array of dosage forms, product types, distribution channels, strengths, end-user segments, and applications, each contributing unique growth drivers and competitive dynamics. Analysis of dosage form reveals that injectable presentations, oral solutions, and tablets each command distinct positions based on clinical setting and patient preference. Product type segmentation highlights branded extended-release and immediate-release offerings alongside generic counterparts in both release profiles, reflecting patent expirations and pricing pressures.

Distribution channel insights indicate that hospital pharmacies, online pharmacies, and retail pharmacies serve as critical conduits for product access, with each channel exhibiting unique reimbursement landscapes and procurement processes. Strength variations, including 50 mg, 100 mg, and 150 mg options, enable tailored dosing regimens to address pain intensity and patient tolerance. End-user segmentation differentiates clinics, home care providers, and hospitals, illuminating how care setting influences formulary decisions and therapy adherence. Finally, application analysis spans acute pain interventions, chronic pain management-including cancer pain and musculoskeletal pain subcategories-and neuropathic pain therapy, underscoring the versatility of tapentadol across therapeutic indications. This multifaceted segmentation framework provides a comprehensive lens for evaluating market penetration and identifying under-leveraged opportunities.

Regional Patterns Illuminating Tapentadol Market Trajectories

Regional dynamics are pivotal in shaping tapentadol adoption and commercial performance, with the Americas, Europe Middle East & Africa, and Asia-Pacific regions exhibiting distinct regulatory frameworks, healthcare infrastructures, and payer models. In the Americas, a balance of private and public reimbursement channels, coupled with progressive opioid stewardship policies, drives nuanced formulary positioning and price negotiation strategies. Pricing frameworks and value-based contracting models are under continuous refinement to align market access with real-world outcome data.

In Europe, Middle East & Africa, heterogeneity in regulatory requirements and reimbursement pathways necessitates localized market entry strategies and adaptive pricing tactics. Collaborative initiatives between regulators and industry stakeholders are accelerating label expansions and post-market safety surveillance programs. In the Asia-Pacific region, evolving healthcare systems and expanding insurance coverage are catalyzing demand for innovative analgesic solutions, while cost-containment measures and tender processes influence channel dynamics and supplier selection. Understanding these regional intricacies is essential for optimizing market penetration and aligning commercial investments with regional growth hotspots.

Competitive Landscape Highlighting Leading Tapentadol Players

The competitive arena for tapentadol features established pharmaceutical innovators alongside emerging generic manufacturers, each leveraging distinct assets to capture market share. Key branded players have fortified their portfolios with extended-release abuse-deterrent formulations to differentiate on safety and adherence metrics. Strategic alliances with research institutions and digital therapeutics providers are enhancing real-world evidence generation and patient support programs.

Generic entrants are capitalizing on patent expirations by introducing cost-effective immediate-release and extended-release formulations, intensifying price competition and driving accessibility. These players often deploy lean manufacturing networks and localized distribution partnerships to maintain competitive pricing while ensuring supply continuity. Collaboration with hospital systems and group purchasing organizations is also becoming more prevalent as generic suppliers seek to expand their footprint in institutional care settings. Observing the evolving strategies of both branded and generic companies provides critical context for anticipating competitive maneuvers and identifying partnership opportunities.

Strategic Recommendations for Maximizing Tapentadol Outcomes

To thrive in the evolving tapentadol market, industry leaders should prioritize a multifaceted approach that balances innovation with operational resilience. First, accelerating the development of abuse-deterrent and extended-release formulations can reinforce clinical differentiation and support premium pricing models. Simultaneously, investing in digital platforms for patient engagement and remote monitoring will enhance therapy adherence and generate real-world evidence to strengthen value propositions.

Second, optimizing supply chain agility through strategic sourcing partnerships and flexible manufacturing capacities will mitigate tariff and input cost volatility. Third, expanding distribution channel coverage by forging alliances with online and retail pharmacy networks can capture diverse patient segments and improve access. Fourth, engaging payers and policymakers through evidence-based health-economic models will facilitate favorable formulary positioning and reimbursement terms. Finally, forging collaborations with leading healthcare systems and patient advocacy groups can deepen market penetration and foster brand loyalty. Collectively, these actions will position market participants to seize emerging opportunities and navigate future uncertainties.

Robust Methodology Underpinning Market Intelligence

This report’s insights are grounded in a rigorous methodology that integrates comprehensive secondary research, in-depth primary interviews, and advanced analytical techniques. Industry data, regulatory filings, and peer-reviewed clinical studies were systematically reviewed to establish a foundational knowledge base. Supplementing this, structured consultations with key opinion leaders across clinical, commercial, and regulatory spheres provided nuanced perspectives on market trends and unmet needs.

Quantitative data were triangulated using multiple sources to ensure reliability, while segmentation analyses were validated through cross-referencing with real-world prescription data. Competitive intelligence was derived from an evaluation of product pipelines, patent landscapes, and corporate financial disclosures. Finally, iterative internal validation sessions and expert panel reviews were conducted to refine findings and ensure alignment with current market realities. This methodological framework ensures the robustness and credibility of the strategic insights presented.

Concluding Perspectives on Tapentadol’s Future Landscape

Tapentadol’s market narrative is one of innovation, adaptation, and strategic realignment amid a complex global healthcare environment. Regulatory advancements, abuse-deterrent technology, and evolving patient engagement models have collectively reshaped its therapeutic positioning. Concurrently, geopolitical factors and tariff fluctuations have underscored the importance of supply chain resilience and cost optimization.

Nuanced segmentation insights and regional analyses reveal how dosage forms, product types, distribution channels, strengths, end-user settings, and applications converge to define market niches and growth corridors. Competitive dynamics, characterized by branded innovation and generic competition, highlight the critical interplay between clinical differentiation and pricing strategies. By synthesizing these multifaceted trends, this executive summary equips stakeholders with an integrated perspective to inform strategic decision-making. As the tapentadol landscape continues to evolve, proactive alignment with emerging opportunities and challenges will be essential for sustaining commercial success and delivering meaningful patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Dosage Form
    • Injectable
    • Oral Solution
    • Tablets
  • Product Type
    • Branded
      • Extended Release
      • Immediate Release
    • Generic
      • Extended Release
      • Immediate Release
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Strength
    • 100 Mg
    • 150 Mg
    • 50 Mg
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Application
    • Acute Pain
    • Chronic Pain
      • Cancer Pain
      • Musculoskeletal Pain
    • Neuropathic Pain
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd
  • Apotex Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Janssen Pharmaceuticals, Inc.
  • Grünenthal GmbH
  • Par Pharmaceutical, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tapentadol Market, by Dosage Form
8.1. Introduction
8.2. Injectable
8.3. Oral Solution
8.4. Tablets
9. Tapentadol Market, by Product Type
9.1. Introduction
9.2. Branded
9.2.1. Extended Release
9.2.2. Immediate Release
9.3. Generic
9.3.1. Extended Release
9.3.2. Immediate Release
10. Tapentadol Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Tapentadol Market, by Strength
11.1. Introduction
11.2. 100 Mg
11.3. 150 Mg
11.4. 50 Mg
12. Tapentadol Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Tapentadol Market, by Application
13.1. Introduction
13.2. Acute Pain
13.3. Chronic Pain
13.3.1. Cancer Pain
13.3.2. Musculoskeletal Pain
13.4. Neuropathic Pain
14. Americas Tapentadol Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Tapentadol Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Tapentadol Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Ltd
17.3.2. Sandoz International GmbH
17.3.3. Mylan N.V.
17.3.4. Sun Pharmaceutical Industries Ltd
17.3.5. Apotex Inc.
17.3.6. Cipla Limited
17.3.7. Dr. Reddy's Laboratories Ltd
17.3.8. Janssen Pharmaceuticals, Inc.
17.3.9. Grünenthal GmbH
17.3.10. Par Pharmaceutical, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TAPENTADOL MARKET MULTI-CURRENCY
FIGURE 2. TAPENTADOL MARKET MULTI-LANGUAGE
FIGURE 3. TAPENTADOL MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TAPENTADOL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TAPENTADOL MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TAPENTADOL MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TAPENTADOL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TAPENTADOL MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TAPENTADOL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TAPENTADOL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TAPENTADOL MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TAPENTADOL MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TAPENTADOL MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TAPENTADOL MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TAPENTADOL MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TAPENTADOL MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TAPENTADOL MARKET SIZE, BY 100 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TAPENTADOL MARKET SIZE, BY 150 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TAPENTADOL MARKET SIZE, BY 50 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TAPENTADOL MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TAPENTADOL MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TAPENTADOL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TAPENTADOL MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TAPENTADOL MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TAPENTADOL MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. CANADA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 61. CANADA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 62. CANADA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 64. CANADA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 67. MEXICO TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. MEXICO TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 70. MEXICO TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 71. MEXICO TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 73. MEXICO TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 113. GERMANY TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 114. GERMANY TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 116. GERMANY TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 117. GERMANY TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 122. FRANCE TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 123. FRANCE TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 125. FRANCE TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 126. FRANCE TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 140. ITALY TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 141. ITALY TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. ITALY TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 143. ITALY TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 144. ITALY TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ITALY TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 146. ITALY TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. ITALY TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. ITALY TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 149. SPAIN TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. SPAIN TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SPAIN TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 152. SPAIN TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 153. SPAIN TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 155. SPAIN TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. SPAIN TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. SPAIN TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 185. DENMARK TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. DENMARK TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. DENMARK TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 188. DENMARK TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 189. DENMARK TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 191. DENMARK TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. DENMARK TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. DENMARK TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 203. QATAR TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. QATAR TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. QATAR TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 206. QATAR TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 207. QATAR TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. QATAR TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 209. QATAR TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. QATAR TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. QATAR TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 212. FINLAND TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. FINLAND TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. FINLAND TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 215. FINLAND TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 216. FINLAND TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 218. FINLAND TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. FINLAND TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 239. EGYPT TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 240. EGYPT TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 242. EGYPT TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 243. EGYPT TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 245. EGYPT TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. EGYPT TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 248. TURKEY TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 249. TURKEY TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. TURKEY TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 251. TURKEY TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 252. TURKEY TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 254. TURKEY TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. TURKEY TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. TURKEY TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 266. NORWAY TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 267. NORWAY TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NORWAY TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 269. NORWAY TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 270. NORWAY TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 272. NORWAY TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. NORWAY TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. NORWAY TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 275. POLAND TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 276. POLAND TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. POLAND TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 278. POLAND TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 279. POLAND TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. POLAND TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 281. POLAND TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. POLAND TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 303. CHINA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 304. CHINA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. CHINA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 306. CHINA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 307. CHINA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. CHINA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 309. CHINA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. CHINA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. CHINA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 312. INDIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 313. INDIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. INDIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 315. INDIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 316. INDIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. INDIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 318. INDIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. INDIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 321. JAPAN TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 322. JAPAN TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. JAPAN TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 324. JAPAN TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 325. JAPAN TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 327. JAPAN TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. JAPAN TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. JAPAN TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 357. THAILAND TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 358. THAILAND TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 359. THAILAND TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 360. THAILAND TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 361. THAILAND TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 362. THAILAND TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 363. THAILAND TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 364. THAILAND TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 365. THAILAND TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 366. PHILIPPINES TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 367. PHILIPPINES TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 368. PHILIPPINES TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 369. PHILIPPINES TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 370. PHILIPPINES TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 371. PHILIPPINES TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 372. PHILIPPINES TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 373. PHILIPPINES TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 374. PHILIPPINES TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 375. MALAYSIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 376. MALAYSIA TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 377. MALAYSIA TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 378. MALAYSIA TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 379. MALAYSIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 380. MALAYSIA TAPENTADOL MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 381. MALAYSIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 382. MALAYSIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 383. MALAYSIA TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 384. SINGAPORE TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 385. SINGAPORE TAPENTADOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 386. SINGAPORE TAPENTADOL MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 387. SINGAPORE TAPENTADOL MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 388. SINGAPORE TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 389. SINGAPORE TAPENTADOL MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tapentadol market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd
  • Apotex Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Janssen Pharmaceuticals, Inc.
  • Grünenthal GmbH
  • Par Pharmaceutical, Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.96 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Tapentadol (CAS 175591-23-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Tapentadol (CAS 175591-23-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030 - Product Image

Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030 - Product Image

Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Tapentadol Market

Tapentadol is an opioid analgesic used to treat moderate to severe pain. It is a centrally acting synthetic analgesic with a dual mechanism of action, acting on both the mu-opioid receptor and the norepinephrine reuptake inhibitor. Tapentadol is available in both immediate-release and extended-release formulations. It is used to treat a variety of conditions, including chronic pain, neuropathic pain, and post-operative pain. Tapentadol is generally well-tolerated and has fewer side effects than other opioids. Tapentadol is a relatively new analgesic on the market, but it has been gaining popularity due to its efficacy and safety profile. It is increasingly being used as an alternative to other opioids, such as oxycodone and hydrocodone. Tapentadol is also being used in combination with other analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs), to provide more effective pain relief. Some of the companies in the Tapentadol market include Grünenthal, Endo Pharmaceuticals, and Purdue Pharma. Grünenthal is the manufacturer of the brand name Tapentadol, while Endo Pharmaceuticals and Purdue Pharma both produce generic versions of the drug. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.